Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
Abstract
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.
INTRODUCTION
A number of genetic alterations have been shown to play a role in the development of follicular cell-derived thyroid cancer. These point mutations and translocations occur in genes of several important signaling pathways, particularly that of the mitogen-activated protein kinase (MAPK) pathway. The MAPK signaling pathway is a master regulator of numerous cellular processes including division, proliferation, differentiation, adhesion, migration, and apoptosis. B-Raf proto-oncogene (BRAF) mutations, RET/papillary thyroid cancer (PTC) rearrangements, and RAS mutations are the most common activators of the MAPK signaling pathway, with significant implications for thyroid tumorigenesis.
BRAF mutations are the most common mutations observed in PTCs, followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers (FTC) are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. While all four of these mutations are common worldwide, the prevalence of each mutation type in thyroid cancer varies significantly, particularly between Asian and Western countries, with the prevalence of PTC significantly higher in Asian countries.
Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter may be predictive of clinicopathologic features, as well as disease prognosis and tumorigenesis in thyroid cancer. Like other common thyroid cancer mutations, the frequency of TERT promoter mutations also appear to differ among countries, though the significance of this observation remains limited due to the small number of studies on this mutation having been conducted to date.
In this article, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer (DTC) in Asians.
BRAF MUTATION
BRAF, located in chromosome 7, is the most commonly mutated gene in thyroid cancers, resulting in potent activation of the MAPK pathway. The most common mutational hotspot in BRAF is T1799A in exon 15, conferring a glutamate to valine substitution at amino acid 600 (V600E) in the BRAF protein. BRAF V600E is the most common genetic alteration in PTC, exhibiting high prevalence in classic PTC and the tall cell variant, although it is generally rare in the follicular variant. Because BRAF mutations can be detected preoperatively in fine needle aspiration biopsy (FNAB) specimens, it is often used in the diagnosis of PTC, and may inform initial treatment strategies. Furthermore, this mutation has emerged as a promising prognostic factor for PTC [12], although the prognostic value of this mutation is still inconclusive [34].
The overall prevalence of BRAF mutations is ~45% (range, 27.3% to 87.1%) [56], with prevalence significantly higher in Asia, especially Korea, relative to Western countries (Table 1) [2356789101112131415161718192021222324]. Although the mechanisms underlying this difference in BRAF mutation frequencies are not well understood, a recent theory suggests that these differences may be associated with higher iodine intake in the Asian populations. Average iodine intakes were 138 to 353 µg/day in the United States [25], 45.3 µg/day in Germany [26], and 226 and 163 µg/day for women and men, respectively, in the United Kingdom [27]. Meanwhile, Japanese and Korean iodine intakes far exceed that of most other countries: 1,565 µg/day in Japan [28] and 479 µg/day in Korea [29]. Furthermore, high iodine intake has been shown to be significantly associated with the occurrence of BRAF mutation [7], though exceptions do exist, including lower BRAF mutation rates in Japan relative to Korea. One possible explanation for this discrepancy may be that of chronic thyroiditis, which is more prevalent in the Korean population. Incidence of Hashimoto's thyroiditis is strongly correlated with the development of PTC [30]. Because the prevalence of Hashimoto's thyroiditis is high in Korea, this positive correlation may provide an explanation for the high incidence of PTC in this country. However, as Hashimoto's thyroiditis is associated with genetic alterations other than BRAF mutations, such as rearrangements of RAS, ERK, and RET/PTC [31], the relationship between BRAF mutations in PTC and chronic thyroiditis requires further assessment.
While geographic differences in the incidence of BRAF mutations are well established, the prevalence of these mutations has changed over time. A recent publication from our laboratory revealed an increase in BRAF-associated thyroid cancers from 62.2% to 73.7% over the last two decades in Korea [8]. Similarly, in the United States, the overall prevalence of BRAF mutations remained stable for an extended period of time (~46%) but increased sharply from 50.0% to 76.9% in the classic papillary form of PTC over the last four decades [9]. More studies on the changes in the mutational rates and its clinical significance will be needed.
RAS MUTATION
RAS mutations are the second most common genetic alteration in thyroid cancer. The RAS gene encodes a family of three isoforms: NRAS, HRAS, and KRAS. Thyroid neoplasms have been associated with mutations in all three isoforms of the RAS gene, although most studies have reported a predominance of NRAS61. RAS point mutations are commonly observed in FTC, as well as the follicular variant PTC. The frequency of RAS mutations in FTC ranges from 10.5% to 56.9% [3233], and is slightly more common in Asia (45.6%) than in Western countries (36.5% in the Americas, and 29.3% in Europe). In contrast, the frequency of RAS mutations in PTC is much lower in Asia (Table 2) [9323334353637383940414243444546474849505152]. This low frequency of RAS mutations has remained relatively stable over time, which is likely to be due to the lower prevalence of follicular variant PTC in this population. In contrast, a study from the United States reported an increase in the proportion of RAS mutation-positive from 2.7% between 1974 and 2000 to 24.9% in 2009, due in part to an increase in the percentage of patients presenting with the follicular variant histology [9].
RAS mutations have been reported in the full spectrum of thyroid neoplasms, limiting the clinical diagnostic value of these mutations. Because it is difficult to differentiate specific types of follicular lesions in thyroid FNAB samples, the diagnostic use of RAS mutations in FNAB specimens remains controversial. The prognostic value of RAS mutations is also unclear, although some evidence suggests that RAS-positive thyroid cancers may be at risk for tumor dedifferentiation, a less favorable prognosis, and metastatic behavior, particularly with regard to bone metastasis [3233].
RET/PTC REARRANGEMENT
Rearrangements of the RET proto-oncogene are commonly seen in PTC, and have been shown to play a role in disease pathogenesis. To date, 13 different types of RET/PTC rearrangements have been reported, though RET/PTC1 and RET/PTC3 account for more than 90% of all rearrangements. The relationship between radiation exposure and RET/PTC rearrangement has been established [5354], with RET/PTC rearrangements frequently observed in PTC patients who have received significant doses of external radiation, such as those affected by the Chernobyl nuclear accident. Elevated levels of childhood PTC are well documented in post-Chernobyl contaminated areas, accompanied by a high prevalence of RET/PTC rearrangements. Rapid proliferation of thyroid cells may account for the high sensitivity to radiation-induced RET/PTC rearrangements among children, although RET/PTC rearrangements also occur more frequently in children and young adults not exposed to radiation [55].
The prevalence of RET/PTC rearrangements in PTC varies widely in different populations (range, 0% to 86.8% [345356]), with significant variability in mutational frequency even within the same geographical regions (0% to 54.5% in Asia [345657], 2.4% to 72.0% in the Americas [958], and 8.1% to 42.9% in Europe [5960]). These discrepancies may be due to the small size of the studies; when this variability is taken into account, the prevalence of RET/PTC rearrangements in Asia is generally low (16.5%) (Table 3) [934425456575859606162636465666768697071].
This wide range of the prevalence rates seen in these studies may reflect not only the geographic variability but also the effect of different detection methods. A variety of methods have been used to identify RET/PTC rearrangements, including reverse transcription polymerase chain reaction methods, Southern blot analysis, and fluorescence in situ hybridization. Zhu et al. [72] demonstrated that different detection methods could result in significant variability in the detection of RET/PTC rearrangement.
PAX8/PPARγ REARRANGEMENT
PAX8/PPARγ rearrangements occur as a result of an intrachromosomal translocation between most of the coding sequence of PAX8 (2q13) and the entire coding exons of PPARγ1 (3p25). The fusion gene appears to be an oncogene, and results in production of a PAX8/PPARγ fusion protein (PPFP). The PAX8/PPARγ fusion gene is most commonly found in FTC, the follicular variant PTC, and benign follicular adenomas, though the prevalence of these rearrangements varies significantly among studies. The mean frequency in FTC is 5.6% in Asia, 43.8% in the Americas, and 27.4% in Europe (Table 4) [36384546737475767778798081828384]. The low frequency of PAX8/PPARγ rearrangements in Asia is particularly noteworthy, with one Japanese study failing to identify a single PAX8/PPARγ rearrangement in FTC [73].
No evidence exists linking PAX8/PPARγ rearrangements with clinical outcomes in FTC. Multiple studies have reported no correlation between PAX8/PPARγ rearrangements and clinical variables such as gender, age, tumor size, lymph node metastasis, recurrence, or mortality [747576].
Despite the lack of clinical associations, PPARγ remains an attractive therapeutic target in thyroid cancer. Although PPARγ agonists have shown promising results in both in vitro and in vivo studies [8586], the results of these studies have been inconclusive. Larger studies with long-term follow-up will be needed to clarify the efficacy and availability of PPARγ agonists in PPFP thyroid cancer.
TERT PROMOTER MUTATION
Somatic mutations in the TERT promoter have been identified in many human malignancies including thyroid cancer. Mutations in the TERT promoter have been shown to increase telomerase activity, which protects the telomere repeats from erosion and plays a key role in cellular immortality and tumorigenesis [87]. TERT promoter mutations were mainly found in two hotspots, located -124 (chr5: 1,295,228C>T) and -146 bp (chr5: 1,295,250C>T) upstream of the gene transcription starting site. These mutations were recently shown to be more prevalent in aggressive thyroid cancers, and were associated with poor prognosis as well as high-risk clinicopathologic features [888990]. Therefore, TERT promoter mutation has received considerable attention as a novel prognostic biomarker. TERT promoter mutations have been shown to coexist with other tumorigenic alterations, such as BRAF or RAS mutations. Indeed, the coexistence of BRAF mutations and TERT promoter mutations has been identified as an indicator of the worst prognosis [8891].
The prevalence of TERT promoter mutation exhibits significant variability among countries ranging from 4.2% to 25.5% [8992] of PTC and 5.9% to 36.4% [9192] of FTC (Table 5) [88899091929394959697]. Among these, the Korean prevalence was noticeably lower than other countries. We analyzed 551 patients with DTC in our institution, with TERT promoter mutations identified in 4.5% of patients [92]. Among 222 DTCs treated at the Catholic University of Korea, the overall prevalence of TERT promoter mutations was 5.4% [93]. The relatively large proportion of small-size tumors in Korea may account for the low frequency of these mutations relative to other countries. TERT promoter mutation assays are difficult to use in routine prognostic testing of DTC, especially in areas where its prevalence is low. Therefore, further studies identifying an optimal subset of TERT promoter mutations may be warranted.
CONCLUSIONS
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis, including a number of genetic alterations involved in the development of follicular cell-derived cancers having been reported. The frequency of each of these mutations varies significantly among populations, with Asian residents exhibiting significantly different mutational profiles relative to Western countries. Korean populations often exhibit different mutation rates relative to other countries, with BRAF mutation rates higher than any other country, whereas RET/PTC and PAX8/PPARγ rearrangements, and TERT promoter mutations, are generally lower. Awareness of the role and prevalence of each mutation may be important for the design of future studies, and may hold promise as either a diagnostic tool or a therapeutic target.
The Prevalence of BRAF Mutations in Papillary Thyroid Cancers
| Study | Country | Year | PTC |
|---|---|---|---|
| Asian total | 6,108/8,884 (68.7) | ||
| Hong et al. (2014) [8] | Korea | 1995-2003 | 120/193 (62.2) |
| Jo et al. (2006) [10] | Korea | 2004-2005 | 102/161 (63.4) |
| Kim et al. (2009) [6] | Korea | 2005-2006 | 88/101 (87.1) |
| Kim et al. (2015) [11] | Korea | 2008-2012 | 2,497/3,019 (82.7) |
| Hong et al. (2014) [8] | Korea | 2009-2012 | 1,792/2,431 (73.7) |
| Takahashi et al. (2007) [12] | Japan | 1956-1993 | 38/64 (59.3) |
| Ito et al. (2009) [3] | Japan | 1996-2000 | 242/631 (38.4) |
| Xing et al. (2013) [2] | Japan | - | 33/49 (67.4) |
| Ito et al. (2014) [13] | Japan | 1996-2001 | 281/766 (36.7) |
| Guan et al. (2009) [7] | China | 1990-2007 | 639/1,032 (61.9) |
| Liu et al. (2014) [14] | China | 2011-2014 | 110/182 (60.6) |
| Lu et al. (2015) [15] | China | 2013-2014 | 121/150 (80.6) |
| Liu et al. (2005) [16] | Taiwan | 1997-2002 | 49/105 (46.7) |
| American total | 559/1,243 (45.0) | ||
| Jung et al. (2014) [9] | USA | 1974-2000 | 81/160 (50.6) |
| Kim et al. (2006) [17] | USA | 2000-2003 | 34/103 (33.0) |
| Jung et al. (2014) [9] | USA | 2009 | 70/169 (41.4) |
| Xing et al. (2013) [2] | USA | - | 316/691 (45.7) |
| Oler et al. (2009) [18] | Brazil | 2000-2007 | 58/120 (48.3) |
| European total | 1,470/3,475 (42.3) | ||
| Frasca et al. (2008) [19] | Italy | 2002-2005 | 125/323 (38.6) |
| Lupi et al. (2007) [20] | Italy | 2006 | 219/500 (43.8) |
| Basolo et al. (2010) [21] | Italy | 2006-2009 | 473/1,060 (44.6) |
| Xing et al. (2013) [2] | Italy | - | 266/551 (48.3) |
| Riesco-Eizaguirre et al. (2006) [22] | Spain | 2000-2003 | 28/67 (41.8) |
| Xing et al. (2013) [2] | Spain | - | 28/66 (42.4) |
| Sykorova et al. (2010) [23] | Czech Republic | 1960-2007 | 81/242 (33.5) |
| Xing et al. (2013) [2] | Czech Republic | - | 71/222 (32.0) |
| Goutas et al. (2008) [5] | Greece | - | 15/55 (27.3) |
| Musholt et al. (2010) [24] | Germany | 1988-2010 | 122/290 (42.1) |
| Xing et al. (2013) [2] | Poland | - | 42/99 (42.4) |
Values are expressed as number/total number (%).
PTC, papillary thyroid cancer.
The Prevalence of RAS Mutations in Well-Differentiated Thyroid Cancers
| Study | Country | Year | PTC | FVPTC | FTC |
|---|---|---|---|---|---|
| Asian total | 9/208 (4.3) | 53/193 (27.5) | 103/226 (45.6) | ||
| Park et al. (1998) [34] | Korea | 1995-1996 | 0/37 (0.0) | - | 1/3 (33.3) |
| Jang et al. (2014) [35] | Korea | 1998-2012 | - | - | 39/85 (45.9) |
| Kim et al. (2012) [36] | Korea | 1999-2004 | - | - | 11/37 (29.7) |
| Park et al. (2013) [37] | Korea | 2000-2011 | - | 35/132 (26.5) | - |
| Jeong et al. (2015) [38] | Korea | 2002-2013 | - | - | 16/35 (45.7) |
| Lee et al. (2013) [39] | Korea | 2011-2012 | - | 18/54 (33.3) | - |
| Naito et al. (1998) [40] | Japan | - | 2/24 (8.3) | - | - |
| Fukahori et al. (2012) [33] | Japan | 1990-2005 | - | - | 33/58 (56.9) |
| Kikuchi et al. (2013) [41] | Japan | - | 2/34 (5.9) | - | - |
| Guo et al. (2014) [42] | China | 2010-2011 | 0/61 (0.0) | 0/7 (0.0) | - |
| Naito et al. (1998) [40] | Taiwan | - | 5/10 (50.0) | - | - |
| Liu et al. (2004) [43] | Taiwan | - | 0/42 (0.0) | - | 3/8 (37.5) |
| American total | 62/408 (15.2) | 68/198 (34.3) | 19/52 (36.5) | ||
| Namba et al. (1990) [44] | USA | - | 3/14 (21.4) | - | - |
| Garcia-Rostan et al. (2003) [32] | USA | - | - | - | 2/19 (10.5) |
| Nikiforova et al. (2003) [45] | USA | - | - | - | 17/33 (51.5) |
| Zhu et al. (2003) [46] | USA | - | 13/76 (17.1) | 13/30 (43.3) | - |
| Jung et al. (2014) [9] | USA | 1974-2000 | 4/149 (2.7) | 4/33 (12.1) | - |
| Rivera et al. (2010) [47] | USA | 1980-2002 | - | 12/47 (25.5) | - |
| Jung et al. (2014) [9] | USA | 2009 | 42/169 (24.9) | 39/88 (44.3) | - |
| European total | 9/81 (11.1) | 6/24 (25.0) | 17/58 (29.3) | ||
| Lemoine et al. (1989) [48] | UK | - | - | - | 4/10 (40.0) |
| Esapa et al. (1999) [49] | UK | - | - | - | 4/9 (44.4) |
| Basolo et al. (2000) [50] | Italy | - | 3/31 (9.7) | - | 2/5 (40.0) |
| Vasko et al. (2003) [51] | France | - | - | - | 7/34 (20.6) |
| Di Cristofaro et al. (2006) [52] | France | - | 6/50 (12.0) | 6/24 (25.0) | - |
Values are expressed as number/total number (%).
PTC, papillary thyroid cancer; FVPTC, follicular variant papillary thyroid cancer; FTC, follicular thyroid cancer.
The Prevalence of RET/PTC Rearrangements in Papillary Thyroid Cancers
| Study | Country | Year | PTCa |
|---|---|---|---|
| Asian total | 46/279 (16.5) | ||
| Park et al. (1998) [34] | Korea | 1995-1996 | 0/24 (0.0) |
| Chung et al. (1999) [61] | Korea | 1996-1999 | 4/31 (12.9) |
| Ishizaka et al. (1989) [62] | Japan | - | 1/11 (9.1) |
| Namba et al. (1991) [56] | Japan | - | 0/10 (0.0) |
| Wajjwalku et al. (1992) [63] | Japan | - | 1/38 (2.6) |
| Motomura et al. (1998) [64] | Japan | 1987-1994 | 4/11 (36.4) |
| Nibu et al. (2005) [65] | Japan | - | 12/40 (30.0) |
| Lee et al. (1998) [57] | Taiwan | 1995-1996 | 6/11 (54.5) |
| Lam et al. (1998) [66] | Hong Kong | 1996-2000 | 17/40 (42.5) |
| Guo et al. (2014) [42] | China | 2010-2011 | 1/63 (1.6) |
| American total | 166/622 (26.7) | ||
| Tallini et al. (1998) [67] | USA | - | 81/201 (40.3) |
| Rhoden et al. (2004) [58] | USA | - | 18/25 (72.0) |
| Jung et al. (2014) [9] | USA | 1974-2000 | 12/141 (8.5) |
| Jung et al. (2014) [9] | USA | 2009 | 4/169 (2.4) |
| Sugg et al. (1999) [68] | Canada | - | 51/86 (59.3) |
| European total | 71/403 (17.6) | ||
| Mayr et al. (1998) [59] | Germany | - | 8/99 (8.1) |
| Musholt et al. (2000) [69] | Germany | 1988-1999 | 17/119 (14.3) |
| Di Cristofaro et al. (2005) [60] | France | 1994-2003 | 9/21 (42.9) |
| Cinti et al. (2000) [70] | Italy | - | 13/69 (18.8) |
| Elisei et al. (2001) [54] | Italy | - | 11/47 (23.4) |
| Puxeddu et al. (2003) [71] | Italy | 1995-1999 | 13/48 (27.1) |
Values are expressed as number/total number (%).
PTC, papillary thyroid cancer.
aPost-chernobyl papillary thyroid cancers were excluded.
The Prevalence of PAX8/PPARγ Rearrangements in Well-Differentiated Thyroid Cancers
| Study | Country | Year | PTC | FVPTC | FTC |
|---|---|---|---|---|---|
| Asian total | 0/12 (0.0) | - | 4/72 (5.6) | ||
| Kim et al. (2012) [36] | Korea | 1999-2004 | - | - | 3/31 (9.7) |
| Jeong et al. (2015) [38] | Korea | 2002-2013 | - | - | 1/35 (2.9) |
| Hibi et al. (2004) [73] | Japan | 1989-2000 | 0/12 (0.0) | 0/6 (0.0) | |
| American total | 0/106 (0.0) | 0/30 (0.0) | 74/169 (43.8) | ||
| Nikiforova et al. (2002) [74] | USA | - | - | - | 8/15 (53.3) |
| Nikiforova et al. (2003) [45] | USA | - | - | - | 13/33 (39.4) |
| French et al. (2003) [77] | USA | - | - | - | 11/42 (26.2) |
| Zhu et al. (2003) [46] | USA | - | 0/46 (0.0) | 0/30 (0.0) | - |
| Sahin et al. (2005) [75] | USA | 1996-2000 | - | - | 31/54 (57.4) |
| Giordano et al. (2006) [78] | USA | - | 0/51 (0.0) | - | 7/13 (53.8) |
| Nakabashi et al. (2004) [79] | Brazil | - | 0/9 (0.0) | - | 4/12 (33.3) |
| European total | 0/20 (0.0) | 16/89 (18.0) | 46/169 (27.4) | ||
| Dwight et al. (2003) [80] | Sweden | - | - | - | 10/34 (29.4) |
| Lacroix et al. (2005) [81] | France | - | - | - | 4/23 (17.4) |
| Di Cristofaro et al. (2006) [82] | France | - | 0/20 (0.0) | 1/12 (8.3) | 9/21 (42.9) |
| Castro et al. (2006) [83] | Portugal | - | - | 15/40 (37.5) | 12/27 (45.5) |
| Boos et al. (2013) [76] | Germany | - | - | 0/37 (0.0) | 6/49 (12.2) |
| Sahpaz et al. (2015) [84] | Turkey | 2001-2012 | - | - | 5/15 (33.3) |
Values are expressed as number/total number (%).
PPARγ, peroxisome proliferator-activated receptor γ; PTC, papillary thyroid cancer; FVPTC, follicular variant papillary thyroid cancer; FTC, follicular thyroid cancer.
The Prevalence of TERT Promoter Mutations in Well-Differentiated Thyroid Cancers
| Study | Country | Year | PTC | FTC |
|---|---|---|---|---|
| Asian total | 57/840 (6.8) | 15/141 (10.7) | ||
| Song et al. (2015) [92] | Korea | 1993-2012 | 18/432 (4.2) | 7/119 (5.9) |
| Jung et al. (2015) [93] | Korea | - | 12/222 (5.4)a | - |
| Liu et al. (2014) [91] | China | - | 39/408 (9.6) | 8/22 (36.4) |
| American total | 91/764 (11.9) | 11/79 (13.9) | ||
| Liu et al. (2013) [94] | USA | - | 30/257 (11.7) | 11/79 (13.9) |
| Xing et al. (2014) [88] | USA | 1990-2012 | 61/507 (12.0) | - |
| European total | 81/686 (11.8) | 37/216 (17.1) | ||
| Liu et al. (2014) [89] | Sweden | - | 13/51 (25.5) | 8/36 (22.2) |
| Wang et al. (2014) [95] | Sweden | 1986-2004 | 25/332 (7.5) | 9/52 (17.3) |
| Melo et al. (2014) [90] | Portugal, Spain | - | 22/182 (12.1) | 12/70 (17.1) |
| Muzza et al. (2015) [96] | Italy | - | 21/121 (17.4) | 8/58 (13.8) |
| Gandolfi et al. (2015) [97] | Italy | 1979-2013 | - | - |
Values are expressed as number/total number (%).
TERT, telomerase reverse transcriptase; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer.
aThese data include both FTC and PTC, and are therefore not included in the total results.
Footnotes
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
References
- 1. Prognostic utility of BRAF mutation in papillary thyroid cancerMol Cell Endocrinol20103218693[PubMed][Google Scholar]
- 2. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancerJAMA201330914931501[PubMed][Google Scholar]
- 3. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patientsEndocr J2009568997[PubMed][Google Scholar]
- 4. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinomaClin Endocrinol (Oxf)200563588593[PubMed][Google Scholar]
- 5. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohortAnticancer Res2008281A305308[PubMed][Google Scholar]
- 6. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditisThyroid200919137141[PubMed][Google Scholar]
- 7. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancerJ Clin Endocrinol Metab20099416121617[PubMed][Google Scholar]
- 8. The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decadesEndocrinol Metab (Seoul)201429505513[PubMed][Google Scholar]
- 9. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutationsJ Clin Endocrinol Metab201499E276E285[PubMed][Google Scholar]
- 10. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancerJ Clin Endocrinol Metab20069136673670[PubMed][Google Scholar]
- 11. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinomaSurgery2015
6 25 [Epub][PubMed][Google Scholar] - 12. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation doseMol Carcinog200746242248[PubMed][Google Scholar]
- 13. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?World J Surg201438679687[PubMed][Google Scholar]
- 14. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese populationInt J Clin Exp Pathol2014769226928[PubMed][Google Scholar]
- 15. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinomaInt J Clin Exp Pathol20158793799[PubMed][Google Scholar]
- 16. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in TaiwanClin Endocrinol (Oxf)200563461466[PubMed][Google Scholar]
- 17. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinomaAnn Surg2006244799804[PubMed][Google Scholar]
- 18. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genesCancer2009115972980[PubMed][Google Scholar]
- 19. BRAF(V600E) mutation and the biology of papillary thyroid cancerEndocr Relat Cancer200815191205[PubMed][Google Scholar]
- 20. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinomaJ Clin Endocrinol Metab20079240854090[PubMed][Google Scholar]
- 21. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 casesJ Clin Endocrinol Metab20109541974205[PubMed][Google Scholar]
- 22. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membraneEndocr Relat Cancer200613257269[PubMed][Google Scholar]
- 23. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech RepublicJ Endocrinol Invest201033318324[PubMed][Google Scholar]
- 24. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodulesWorld J Surg20103425952603[PubMed][Google Scholar]
- 25. US Food and Drug Administration's Total Diet Study: dietary intake of perchlorate and iodineJ Expo Sci Environ Epidemiol200818571580[PubMed][Google Scholar]
- 26. Scientific Committee on FoodOpinion of the scientific committee on food on the tolerable upper intake level of iodineBrusselsEuropean Commission, Health & Consumer Protection Directorate-General2002
- 27. Expert Group on Vitamins and MineralsSafe upper levels for vitamins and mineralsLondonFood Standards Agency2003
- 28. Ministry of Health, Labour and WelfareDietary reference intakes for JapaneseTokyoNational Institute of Health and Nutrition2010
- 29. Dietary iodine intake and urinary iodine excretion in normal Korean adultsYonsei Med J199839355362[PubMed][Google Scholar]
- 30. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditisHead Neck201133691695[PubMed][Google Scholar]
- 31. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean populationThyroid20071710311038[PubMed][Google Scholar]
- 32. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancerJ Clin Oncol20032132263235[PubMed][Google Scholar]
- 33. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohortThyroid201222683689[PubMed][Google Scholar]
- 34. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean populationClin Endocrinol (Oxf)199849317323[PubMed][Google Scholar]
- 35. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinomaThyroid20142412751281[PubMed][Google Scholar]
- 36. Frequency of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors in KoreaEndocrinol Metab (Seoul)2012274553[Google Scholar]
- 37. BRAF and RAS mutations in follicular variants of papillary thyroid carcinomaEndocr Pathol2013246976[PubMed][Google Scholar]
- 38. Analysis of RAS mutation and PAX8/PPARgamma rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findingsJ Endocrinol Invest201538849857[PubMed][Google Scholar]
- 39. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testingThyroid20132314161422[PubMed][Google Scholar]
- 40. Different ras gene mutational frequencies in thyroid papillary carcinomas in Japan and ThailandCancer Lett1998131171175[PubMed][Google Scholar]
- 41. Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutationFront Genet20134271[PubMed][Google Scholar]
- 42. Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland ChinaDis Markers20142014912182[PubMed][Google Scholar]
- 43. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in TaiwanThyroid200414616621[PubMed][Google Scholar]
- 44. Point mutations of ras oncogenes are an early event in thyroid tumorigenesisMol Endocrinol1990414741479[PubMed][Google Scholar]
- 45. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinomaJ Clin Endocrinol Metab20038823182326[PubMed][Google Scholar]
- 46. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutationsAm J Clin Pathol20031207177[PubMed][Google Scholar]
- 47. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patternsMod Pathol20102311911200[PubMed][Google Scholar]
- 48. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesisOncogene19894159164[PubMed][Google Scholar]
- 49. Prevalence of Ras mutations in thyroid neoplasiaClin Endocrinol (Oxf)199950529535[PubMed][Google Scholar]
- 50. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expressionThyroid2000101923[PubMed][Google Scholar]
- 51. Specific pattern of RAS oncogene mutations in follicular thyroid tumorsJ Clin Endocrinol Metab20038827452752[PubMed][Google Scholar]
- 52. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variantHum Pathol200637824830[PubMed][Google Scholar]
- 53. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in childrenCancer Res19975716901694[PubMed][Google Scholar]
- 54. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adultsJ Clin Endocrinol Metab20018632113216[PubMed][Google Scholar]
- 55. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adultsJ Clin Endocrinol Metab20008511701175[PubMed][Google Scholar]
- 56. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumorsEndocrinol Jpn199138627632[PubMed][Google Scholar]
- 57. High frequency of rearrangement of the RET protooncogene (RET/PTC) in Chinese papillary thyroid carcinomasJ Clin Endocrinol Metab19988316291632[PubMed][Google Scholar]
- 58. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinomaLab Invest20048415571570[PubMed][Google Scholar]
- 59. Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinomaBr J Cancer199877903906[PubMed][Google Scholar]
- 60. ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patientsEndocr Relat Cancer200512173183[PubMed][Google Scholar]
- 61. Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomasThyroid1999912371243[PubMed][Google Scholar]
- 62. Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy-termini due to alternative splicingOncogene19894789794[PubMed][Google Scholar]
- 63. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomasJpn J Cancer Res199283671675[PubMed][Google Scholar]
- 64. ret rearrangements in Japanese pediatric and adult papillary thyroid cancersThyroid19988485489[PubMed][Google Scholar]
- 65. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomasEur Arch Otorhinolaryngol2005262368373[PubMed][Google Scholar]
- 66. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parametersHum Pathol199829565568[PubMed][Google Scholar]
- 67. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypesClin Cancer Res19984287294[PubMed][Google Scholar]
- 68. Oncogene profile of papillary thyroid carcinomaSurgery19991254652[PubMed][Google Scholar]
- 69. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinomaSurgery2000128984993[PubMed][Google Scholar]
- 70. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISHCytogenet Cell Genet2000885661[PubMed][Google Scholar]
- 71. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomasEur J Endocrinol2003148505513[PubMed][Google Scholar]
- 72. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneityJ Clin Endocrinol Metab20069136033610[PubMed][Google Scholar]
- 73. Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNAEndocr J200451361366[PubMed][Google Scholar]
- 74. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analysesAm J Surg Pathol20022610161023[PubMed][Google Scholar]
- 75. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic valueJ Clin Endocrinol Metab200590463468[PubMed][Google Scholar]
- 76. Diagnostic and prognostic implications of the PAX8-PPARgamma translocation in thyroid carcinomas-a TMA-based study of 226 casesHistopathology201363234241[PubMed][Google Scholar]
- 77. Genetic and biological subgroups of low-stage follicular thyroid cancerAm J Pathol200316210531060[PubMed][Google Scholar]
- 78. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocationClin Cancer Res2006127 Pt 119831993[PubMed][Google Scholar]
- 79. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinomaClin Endocrinol (Oxf)200461280282[PubMed][Google Scholar]
- 80. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumorsJ Clin Endocrinol Metab20038844404445[PubMed][Google Scholar]
- 81. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterationsAm J Pathol2005167223231[PubMed][Google Scholar]
- 82. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genesEndocr Relat Cancer200613485495[PubMed][Google Scholar]
- 83. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinomaJ Clin Endocrinol Metab200691213220[PubMed][Google Scholar]
- 84. BRAF (V600E) mutation, RET/PTC1 and PAX8-PPAR gamma rearrangements in follicular epithelium derived thyroid lesions: institutional experience and literature reviewBalkan Med J201532156166[PubMed][Google Scholar]
- 85. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell linesThyroid200515222231[PubMed][Google Scholar]
- 86. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cellsEndocrinology200614744634475[PubMed][Google Scholar]
- 87. Specific association of human telomerase activity with immortal cells and cancerScience199426620112015[PubMed][Google Scholar]
- 88. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceJ Clin Oncol20143227182726[PubMed][Google Scholar]
- 89. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomasOncogene20143349784984[PubMed][Google Scholar]
- 90. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomasJ Clin Endocrinol Metab201499E754E765[PubMed][Google Scholar]
- 91. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancerJ Clin Endocrinol Metab201499E1130E1136[PubMed][Google Scholar]
- 92. The effects of TERT promoter mutation and coexisting mutations on poor outcome in thyroid cancer
Paper presented at: 2015 Seoul International Congress of Endocrinology and Metabolism 2015 Apr 30-May 3 Seoul, Korea - 93. The role of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
Paper presented at: Annual Autumn Meeting of the Korean Thyroid Association 2015 Aug 28-29 Daegu, Korea - 94. Highly prevalent TERT promoter mutations in aggressive thyroid cancersEndocr Relat Cancer201320603610[PubMed][Google Scholar]
- 95. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTACancer201412029652979[PubMed][Google Scholar]
- 96. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localizationMol Cell Endocrinol2015399288295[PubMed][Google Scholar]
- 97. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinomaEur J Endocrinol2015172403413[PubMed][Google Scholar]